The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
NCT03906123, Not applicable, Unknown, Tianjin Medical University General Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia | ClinicalTrials.gov |
| NCT number | NCT03906123 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 64 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Tianjin Medical University General Hospital | ClinicalTrials.gov |
| Conditions | Subcortical Vascular Dementia, Cerebral Small Vessel Diseases | ClinicalTrials.gov |
| Interventions | NBP, Placebos | ClinicalTrials.gov |
| First posted | 2019-04-08 | ClinicalTrials.gov |
| Last updated | 2019-04-08 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Auditory Verbal Learning Test (AVLT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | AVLT is used to evaluate verbal learning and memory ability. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Brief Visuospatial Memory Test-Revised (BVMT-R) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | BVMT-R is used to evaluate spatial memory ability. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Digital span (DS) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | DS is used to assess attention. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Symbol Digit Modalities Test (SDMT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | SDMT is used to assess information processing speed. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Trail Making Test-A (TMT-A) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | TMT-A is used to assess information processing speed. Lower score indicates better performance. | ClinicalTrials.gov |
| Primary | TMT-B at endpoint and change from baseline | 48 weeks post-dose and change from baseline | TMT-B is used to assess executive function. Lower score indicates better performance. | ClinicalTrials.gov |
| Primary | Stroop test at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Stroop test is used to assess executive function. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Benton Judgment of Line Orientation (JLO) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | JLO is used to assess visuospatial function. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Verbal fluency test at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Verbal fluency test is used to evaluate language function. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Boston Naming Test (BNT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | BNT is used to evaluate language function. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Controlled Oral Word Association Test (COWAT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | COWAT is used to evaluate language function. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Mini-Mental State Examination (MMSE) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | MMSE is used to evaluate global cognition. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment (MoCA) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | MoCA is used to evaluate global cognition. Higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Activity of daily living (ADL) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | ADL is used to evaluate activities of daily living. | ClinicalTrials.gov |
| Secondary | Global function at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Clinical Dementia Rating (CDR) is used to evaluate global function. | ClinicalTrials.gov |
| Secondary | Neuropsychiatric Inventory (NPI) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | NPI is used to evaluate behavioral and psychological symptoms of dementia (BPSD). | ClinicalTrials.gov |
| Other | Hamilton Depression Scale (HAMD) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | HAMD is used to evaluate depressive symptoms. | ClinicalTrials.gov |
| Other | Geriatric Depression Scale (GDS) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | GDS is used to evaluate depressive symptoms. | ClinicalTrials.gov |
| Other | Regulation of endothelial progenitor cell at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Circulating endothelial progenitor cell (EPC) is detected with flow cytometry. | ClinicalTrials.gov |
| Other | Transcranial Doppler (TCD) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | TCD is used to measure cerebral blood flow. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 8
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Line Angle Matching | Primary outcome | ConductCognition |
| Picture Naming Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)